| PFE |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$14.65B vs. cons $14.38B |
MEDIUM |
| PFE |
Report |
Vyndaqel Family Revenue (Q2 2026) |
MISS |
pred ~$1.65B vs. cons $1.702B |
MEDIUM |
| PFE |
Report |
Padcev Revenue (Q2 2026) |
BEAT |
pred ~$660M vs. cons $630M |
MEDIUM |
| PFE |
Guide |
FY 2026 Revenue (full year) |
LOWER |
guide mid ~$61.0B vs. cons $61.76B |
HIGH |
| PFE |
Guide |
FY 2026 Adj. EPS (full year) |
LOWER |
guide mid ~$2.90 vs. cons $2.94 |
HIGH |
| PFE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.5% |
— |
MEDIUM |
| PFE |
Return |
5-day cumulative residual |
-2.0% (FADE) |
FADE — implicit H2 estimate cuts pull stock lower as sell-side models are updated post-print |
MEDIUM |